New ILAE Seizure Classification
Friday, 10 March 2017
FIRST AID
Know what to do when a seizure happens in front of you.
DONATE NOW
We rely heavily on community support to achieve our goal.
LEAVE A LEGACY
A bequest is an easy way to support Epilepsy New Zealand.
VOLUNTEERS NEEDED!
We need your help! View our list of volunteer roles to see how you can make a difference or gain valuable work experience.
FUNDRAISER
We need your help! If your
interested in fundraising
for us, register today!
THANK YOU!
We would not be here without our supporters! Find out who our supporters are.
Friday, 10 March 2017
Patients taking lamotrigine who have concerns about the change can talk to their doctor about remaining on the current brand as PHARMAC has widened the criteria for lamotrigine exceptional circumstances.
Epilepsy New Zealand President Dr Peter Bergin welcomes the news that Pharmac are now allowing people who have been stable on their previous brands of lamotrigine to continue taking their original brand.
If you have visited your doctor recently to seek advice on the brand changes for lamotrigine, your GP can waive the co-payment you would normally pay.
From 01 Oct 2019, Pharmac only funds the generic brand of Lamotrigine, called Logem. They no longer fund the Lamictal and Arrow brands. Tell us how it's going for you.
BPAC issues new guidelines for Lamotrigine.
A petition is underway calling on Pharmac to reverse its decision on Lamotrigine.
We opposed this change from Lamictal to Logem from the start, and staff have advocated on behalf of people with epilepsy in discussions with Pharmac.
Ashleigh is a great young woman from Canterbury, this story is written about her epilepsy by her mother, she is heading to Cleveland for epilepsy treatment.
Adele Hauwai has shared her Living With Epilepsy story as part of the Epilepsy NZ Tell Us About It Competition. People were asked to send in their stories about epilepsy, the challenges they faced and the lessons they have learned that they would like to share with the world.
The ILAE announces the publication in Epilepsia of two new landmark classification documents, one of seizure types and one of the epilepsies.